secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2025-07-14T23:59:59+00:00
Accession:  0001193125-25-158719
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atara resubmits tab-cel BLA to FDA for EBV+ PTLD; cash ~$22M, runway into Q1 2026
--------------------------------------------------------------------------------

- Atara resubmitted BLA to FDA for tabelecleucel (tab-cel) for EBV+ PTLD after CRL related to manufacturing observations.
- Pivotal ALLELE study showed 48.8% ORR (p<0.0001); no FDA-approved therapies in this setting.
- Cash, cash equivalents and short-term investments ~$22M as of June 30, 2025; cost cuts extend runway into Q1 2026.
- $40M milestone payment from Pierre Fabre due upon FDA approval; plus double-digit tiered royalties on net sales.
- Transitioning tab-cel clinical studies to Pierre Fabre; Atara maintains BLA sponsorship.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000119312525158719/0001193125-25-158719-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000119312525158719/d63996d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-158719

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer